Patient characteristics by age group
| Demographics | Group 1 (⩽50 years) | Group 2 (51–64 years) | Group 3 (⩾65 years) |
|---|---|---|---|
| No of patients | 81 | 254 | 115 |
| Males (%) | 64 (79%) | 234 (92%) | 96 (83%) |
| Mean (SD) age (years) | 39 (11) | 58 (4) | 70 (3) |
| Range | 7–50 | 51–64 | 65–78 |
| Mean (SD) follow up (months) | 30 (24) | 30 (26) | 19 (20) |
| Range | < 1–114 | < 1–112 | < 1–107 |
| Underlying disease | |||
| CAD | 36 (44%) | 188 (74%) | 86 (75%) |
| DCM | 18 (22%) | 42 (17%) | 16 (14%) |
| R/LVD | 5 (6%) | 8 (3%) | 6 (5%) |
| Other | 22 (27%) | 16 (6%) | 7 (6%) |
| ACVB | 7 (9%) | 49 (19%) | 24 (21%) |
| Vessel disease | |||
| 0 | 40 (49%) | 72 (28%) | 31 (27%) |
| 1 vessel | 14 (17%) | 49 (19%) | 27 (23%) |
| 2 vessels | 10 (12%) | 66 (26%) | 29 (25%) |
| 3 vessels | 17 (21%) | 67 (26%) | 28 (24%) |
| Left ventricular ejection fraction | |||
| Mean (SD), % | 36 (16) | 32 (13) | 39 (15) |
| Range | 12–85 | 12–85 | 15–77 |
| <40% | 49 (60%) | 187 (74%) | 61 (53%) |
| ⩾40% | 32 (40%) | 67 (26%) | 54 (47%) |
| Arrhythmia history | |||
| No arrhythmias | 3 (4%) | 8 (3%) | 4 (3%) |
| SMVT | 16 (20%) | 90 (35%) | 38 (33%) |
| VF | 35 (43%) | 59 (23%) | 32 (28%) |
| SMVT+VF | 27 (33%) | 97 (38%) | 40 (35%) |
| Heart failure | |||
| NYHA I | 24 (30%) | 26 (10%) | 6 (5%) |
| NYHA II | 19 (23%) | 109 (43%) | 44 (38%) |
| NYHA II-III | 20 (25%) | 72 (28%) | 34 (30%) |
| NYHA III | 18 (22%) | 47 (19%) | 31 (27%) |
| No of failed antiarrhythmic drugs (SD) | 3 (2) | 3 (2) | 3 (2) |
| Range | 1–8 | 1–13 | 1–11 |
CAD, coronary artery disease; DCM, dilated cardiomyopathy; R/LVD, right/left ventricular dysplasia; NYHA, New York Heart Association functional class of heart failure; SMVT, sustained monomorphic ventricular tachycardia; VF, ventricular fibrillation.